Abivax is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory diseases. Its lead program, obefazimod, targets conditions such as ulcerative colitis by modulating immune pathways rather than relying on classic immunosuppressants alone. With little commercial product revenue, value hinges on late-stage clinical progress and potential partnerships for inflammatory bowel disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -48.4 | — |
| Q3 2025 | 0 | — | -153.4 | — |
| Q4 2025 | 0 | — | -82 | — |
| Q1 2026 | 0 | — | -48.5 | — |
| Q2 2026 | 0 | — | -117.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: HealthEquity, Inc. (HQY), BOK Financial Corporation (BOKF), Kratos Defense & Security Solutions, Inc. (KTOS), AppFolio, Inc. (APPF), Spyre Therapeutics, Inc. (SYRE), The Descartes Systems Group Inc. (DSGX)